Connect® Myeloid Disease Registry

Purpose

The purpose of the Connect® Myeloid disease registry is to provide unique insights into treatment decisions and treatment patterns as they relate to clinical outcomes of patients with myeloid diseases in routine clinical practice. This disease registry will also evaluate molecular and cellular markers that may provide further prognostic classification which may or may not be predictive of therapy and clinical outcomes.

Conditions

  • Primary Myelofibrosis
  • Myelodysplastic Syndromes
  • Leukemia, Myeloid, Acute

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Patients must be able to provide written informed consent form (ICF) - Must be willing and able to complete baseline and follow-up HRQoL instruments, for which patients must be proficient in either English or Spanish - AML patients must be at least 55 years of age at the time of informed consent. - MF, ICUS, and MDS patients must be at least 18 years of age at the time of informed consent. Newly diagnosed Idiopathic Cytopenias of Undetermined Significance (ICUS), Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) patients: - Newly diagnosed primary or secondary disease. To be considered "newly diagnosed", a patient's confirmed diagnosis must be made no more than 60 days prior to the date of consent signature. (An additional 5-day window [i.e., up to 65 days prior to the date of ICF signature] may be allowed in special circumstance upon sponsor approval) - Cohort assignment confirmed by central eligibility review. Cohort assignment must also be confirmed by the site. Myelofibrosis (MF) patients: - Patients who initiated their first active systemic treatment for MF and/or MF-related cytopenias within 90 days prior to the date of consent signature. This cohort allows the enrollment of subjects with a diagnosis of Myelodysplastic/Myeloproliferative overlap syndromes (MDS/MPN overlap syndrome). - Cohort assignment is confirmed by the site. Central eligibility review is not required. Treated Lower-Risk Myelodysplastic Syndromes (LR-MDS) patients: - Patients who have initiated first active treatment regimen containing at least one non-ESA therapy, within 90 days prior to ICF - Cohort assignment is confirmed by site. Central eligibility review is not required.

Exclusion Criteria

  • Suspected or proven acute promyelocytic leukemia (APL) (FAB M3 or WHO 2008) based on morphology, immunophenotype, molecular assay or karyotype - Currently enrolled in any interventional clinical trial where the patient is being treated with an investigational product that cannot be identified. - Idiopathic Cytopenias of Undetermined Significance (ICUS), Myelodysplastic Syndromes (MDS) patients who received or are receiving active (disease modifying) therapy for the treatment of MDS prior to the date of informed consent. - Acute Myeloid Leukemia (AML) patients who initiated active (disease modifying treatment for AML more than 2 weeks prior to the date of consent. - Myelofibrosis (MF) and Myelodysplastic/Myeloproliferative (MDS/MPN) overlap syndrome patients with suspected juvenile myelomonocytic leukemia (JMML).

Study Design

Phase
Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Arm Groups

ArmDescriptionAssigned Intervention
Newly diagnosed Lower-Risk Myelodysplastic Syndromes (LR-MDS) Newly diagnosed lower risk MDS patients as determined by International Prognostic Scoring System (IPSS).
Newly diagnosed Higher-Risk Myelodysplastic Syndromes (HR-MDS) Newly diagnosed higher risk MDS patients as determined by International Prognostic Scoring System (IPSS).
Newly diagnosed Acute Myeloid Leukemia (AML) Newly diagnosed AML patients (≥55 years old, excluding patients with acute promyelocytic leukemia (APL).
Treated Myelofibrosis (MF) Newly treated MF patients receiving treatment for MF or MF-related cytopenias. This cohort also includes patients with myelodysplastic syndrome (MDS)/myeloproliferative neoplasm (MPN) overlap syndromes, excluding juvenile myelomonocytic leukemia (JMML).
Newly diagnosed Idiopathic cytopenia of undetermined significance (ICUS) Newly diagnosed ICUS patients.
Treated Lower-Risk Myelodysplastic Syndromes (LR-MDS) Treated LR-MDS patients receiving first active treatment regimen containing at least one non-ESA therapy

Recruiting Locations

More Details

Status
Recruiting
Sponsor
Celgene

Study Contact

BMS Study Connect Contact Center www.BMSStudyConnect.com
855-907-3286
Clinical.Trials@bms.com

Detailed Description

This Disease Registry will collect data on patient characteristics, treatment patterns and clinical outcomes. The objective is to describe how patients with myeloid diseases are treated; and to build a knowledge base regarding the effectiveness and safety of first line and subsequent treatment regimens in both community and academic settings. Enrolled patients will receive treatment and evaluations for their disease according to the standard of care and routine clinical practice at each study site. All treatments that patients receive for their disease will be recorded, including initial treatment and any subsequent therapy. Data on treatment outcomes, including response rates as measured by the treating physician, evidence of progression, survival, and patient-reported outcomes will be collected quarterly on the electronic CRF.